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Current rare-variant, gene-based tests of association often suffer from a lack of statistical power to detect
genotype–phenotype associations as a result of a lack of prior knowledge of genetic disease models combined
with limited observations of extremely rare causal variants in population-based samples. The use of pedigree data,
in which rare variants are often more highly concentrated than in population-based data, has been proposed as 1
possible method for enhancing power. Methods for combining multiple gene-based tests of association into a
single summary p value are a robust approach to different genetic architectures when little a priori knowledge is
available about the underlying genetic disease model. To date, however, little consideration has been given to
combining gene-based tests of association for the analysis of pedigree data. We propose a flexible framework for
combining any number of family-based rare-variant tests of association into a single summary statistic and for
assessing the significance of that statistic. We show that this approach maintains type I error and improves the
robustness, to different genetic architectures, of the statistical power of family- and gene-based rare-variant tests
through application to simulated phenotype data from Genetic Analysis Workshop 19.Background
Over the past decade, the rapid decrease in costs for
DNA sequence data have made it possible to consider
the association of rare single nucleotide variants (SNVs)
and complex disease phenotypes. However, the power of
any single variant test of genetic association on such rare
variants is limited. As such, many gene-based tests of
association (simultaneously testing all variants within a
gene) have recently been proposed, with the intent to
improve statistical power over single marker association
tests. Recent insights have classified most of these gene-* Correspondence: nathan.tintle@dordt.edu
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(alternatively: collapsing, length, linear) tests and vari-
ance component (alternatively: joint, quadratic) tests [1].
Burden tests collapse rare-variant signal into a single
measure of total rare-variant “burden,” which is then
tested for association with the phenotype. Variance com-
ponent tests determine the strength of association of a
particular variant site with observed trait values, and
then aggregate these associations across all variants in
the gene.
Despite improvements over single-marker approaches,
gene-based tests may still have limited utility in detect-
ing causal rare variants because of an overall lack of
power. This lack of power is exacerbated by the fact that
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ance component test) requires some a priori knowledge
of the underlying genetic architecture. In particular, bur-
den tests are most powerful when the variants within a
SNV set are mostly causal and have the same causal
direction, whereas variance component tests perform
optimally in circumstances where the causal direction
varies (ie, in the presence of both risk-reducing and risk-
increasing SNVs) [1], even for family data [2].
In response, new tests of association have been pro-
posed that simultaneously leverage the strengths of both
burden and variance component tests [3–5]. These
methods generally propose computing a burden test p-
value and a variance components test p-value on the
same SNV set, then using some method to combine the
individual p values from the gene-based tests of associ-
ation into one summary p value for the gene, but are fre-
quently limited by not being applicable to family-based
data. One exception is the seqMeta package in R [6].
The use of family/pedigree data has become popular
as another means of increasing statistical power to de-
tect causal rare variants. Rare SNVs are more concen-
trated in affected families, meaning that causal SNVs
may aggregate in pedigree data more than in the general
population or in a traditional case-control study. In this
article, we propose a general method of combining dif-
ferent rare-variant tests for use on family-based data.
We then quantify to what extent combining family-based
rare-variant tests of association increases power and main-
tains type I error rate for simulated phenotypes using data
from Genetic Analysis Workshop 19 (GAW19).
Methods
General combination strategy
Our approach, which extends the approach by Derkach
et al [5] to the case of family-based data, combines p
values across a variety of family-based gene-level rare-
variant tests of association into a single summary statis-
tic. Given a set of k distinct family- and gene-based rare-
variant tests of association, the method involves the
following 5 steps: (a) Generate a vector of test statistics
Q 0ð Þ = (Q1;…; QkÞ, where Qi represents the test statistic
for the ith family-based rare-variant test of association
(i = 1, …, k). (b) Permute the phenotype of interest m
times. Find Q 1ð Þ; …; Q mð Þ; where Q jð Þ is the vector of
test statistics generated from the jth permutation (j =
1,…, m). (See next paragraph for consideration of
pedigree structure.) (c) Convert each test statistic vec-
tor, Q jð Þ , to a corresponding vector of p values, where
p jð Þ ¼ p jð Þ1 ; …; p jð Þk
 
. p jð Þi is calculated empirically, with
p jð Þi ¼
rank Q jð Þið Þ




= 1 for the most
extreme value of Q1 across all m permutations, andrank Q jð Þi
 
¼ m for the smallest value of Qi across all
permutations. (d) Find all S jð Þ ¼ f p jð Þ  , where S is a
univariate statistic calculated by combining p jð Þ1 ;…; p
jð Þ
k
for the jth permutation. In this article we use
S jð Þ ¼ f p jð Þ  ¼ argmin p jð Þ1 ;…; p jð Þk
n o
, although other p
value combination options are possible. (e) Compute
the significance level of S 0ð Þ by finding the percentage
of S jð Þ that are greater than S 0ð Þ, out of m.
Permuting phenotype values when pedigree structure
exists in the samples fails to maintain appropriate type I
error rates. To address this limitation, we modify the
approach listed in the previous paragraph by first fitting a
linear mixed effects model to the desired covariates, with
familial correlation as a random effect, and the phenotype
of interest as the response, as has been done in related set-
tings [7]. We estimated fixed effects parameters for covari-
ates, and the random effects of familial correlation
assuming a covariance matrix proportional to the prespe-
cified kinship matrix. Because the mixed effects model
generates predicted values that account for familial status,
the residuals are independent of kinship, and therefore in-
dependent between subjects. These residuals can then be
permuted among the individuals, and the test statistics
reevaluated with these “new” phenotypes. Thus, in the
previous paragraph, for family data, each Q ið Þ is a function
of the residuals from random effects models.Application
As a proof-of-concept, we applied the above method to
data from GAW19. The data consists of real genotype
data, on which blood pressure phenotypes were simu-
lated, for 849 Mexican American individuals across 20
separate pedigrees. We considered the continuous re-
sponse variable mean arterial pressure (MAP), calculated
as (2/3)*(diastolic blood pressure) + (1/3)*(systolic blood
pressure). We assessed the relationship between MAP
and the 30 genes on chromosome 3 that possess at least
1 casual variant using 1000 permutations per test. Power
was then calculated as the proportion of times among
the 200 individual phenotype simulations where each
gene was found to be significant, using a 0.05 threshold.
Type I error was assessed in a similar method on the
same 30 genes, but with the trait Q1 (which was simu-
lated to be heritable although unrelated to genotype) as
the phenotype of interest.Tests used
We examined 8 different family-based rare variant tests
of association, and compared their individual perform-
ance to the performance of the 8 tests combined. The 8
tests included 4 burden tests and 4 variance component
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variant weighting system, and the power to which the
score statistic for the ith variant, Ui , was raised. In this
case, Ui ¼ y XbB
 0bΣ1gi , where y is the phenotype
vector, X the covariate matrix, bB and bΣ1 the maximum
likelihood estimators for the fixed effect parameters of
the covariates and the inverse of the covariance matrix,
respectively, and gi the i
th genotype vector. In particular,
2 different variant weighting systems were considered.
The weights suggested by Wu et al. [8] for use in the
sequence kernel association test (SKAT), notated as wi
for the ith variant, are calculated using a Beta distribution
and substantially downweight common variants, (wieBeta
MAF ; a1; a2ð Þ; wherea1 anda2 areprespecifiedparametersÞ,
while the weights suggested by Price et al. [9], notated as




is the allele frequency in the controls. Following the
example of Liu et al. [1], we also raised the score statistics
to differing powers, varying the tests’ statistical power in
response to a small proportion of causal variants. In
general, raising score statistics to higher powers makes the
test more robust to the inclusion of noncausal variants.


























iTable 1 Type I error rate for 10 genes selected to be representative
Gene Q2 Q2 Q1 Q1
High power
ARF4 0.055 0.05 0.015 0.0
DNASE1L3 0.055 0.085 0.07 0.0
MAP4 0.06 0.05 0.055 0.0
SCAP 0.09 0.135 0.025 0.0
Low power
CXCR6 0.07 0.045 0.115 0.0
PAK2 0.04 0.095 0.045 0.0
PTPLB 0.005 0.025 0.055 0.0
RAD18 0.045 0.045 0.025 0.0
Other representative genes
PDCD6IP 0.05 0.035 0.055 0.0
ZBTB38 0.065 0.035 0.045 0.0
Mean Across All 30 Genes (SD) 0.067 (0.03) 0.074 (0.05) 0.048 (0.02) 0.0
Type I error rates are reported for all 9 tests across 10 different genes: the 4 genes
genes deemed representative of the remaining genes explored. The mean type I er












We note that Q2 is asymptotically equivalent to famS-
KAT [2], the family-based version of SKAT [8], and Q1
is related to standard burden tests.Results
Type I error
Across all 30 genes, for all tests, the type I error rate
was generally controlled. The average type I error rate
across the 30 genes fell within a range of 0.048 to
0.09 for the 9 different methods, which was within
expected limits (99% confidence interval [CI]: 0.4%,
9.6%) (Table 1).Power
For nearly all genes analyzed, the empirical power was
low, and typically well under 0.35 (Table 2). This was
particularly true for those tests with Q1 or Q1 , which
had substantially lower power; in the case of Q1 this is
likely because the wi weights are designed to be squared,
whereas in the case of Q1 it is likely because common
variants were not excluded, and the wi weights do not
sufficiently downweight common variants relative to rare
variants. However, despite the presence of these 2 under-
powered tests in the combined p value procedure, the
combined test had power in the same range as more
optimal tests. We further note that, depending on the
characteristics of the gene being examined, tests featur-
ing either the wi weights or the wi weights were oftenof all 30 genes explored
 Q4 Q4 Q3 Q3 Combined
3 0.065 0.04 0.04 0.025 0.03
7 0.08 0.075 0.075 0.07 0.055
9 0.085 0.09 0.055 0.06 0.07
55 0.08 0.18 0.055 0.075 0.055
65 0.075 0.065 0.065 0.045 0.04
55 0.04 0.08 0.035 0.055 0.035
15 0.01 0.045 0.01 0.035 0.03
6 0.045 0.035 0.04 0.04 0.03
45 0.055 0.055 0.05 0.045 0.035
2 0.06 0.055 0.055 0.04 0.03
59 (0.05) 0.07 (0.03) 0.084 (0.05) 0.058 (0.03) 0.065 (0.05) 0.058 (0.04)
with highest overall power, the 4 genes with lowest overall power, and 2
ror rate for each test statistic across all 30 genes is reported at the bottom of
ed at a 0.05 level
Table 2 Power for 10 genes selected to be representative of all 30 genes explored
Gene Q2 Q2 Q1 Q1 Q4 Q4 Q3 Q3 Combined
High power
ARF4 0.425 0.315 0.07 0.075 0.885 0.585 0.785 0.435 0.58
DNASE1L3 0.525 0.315 0.13 0.055 0.53 0.365 0.455 0.365 0.325
MAP4 0.995 0.995 0.225 0.99 0.995 0.995 0.995 0.995 0.995
SCAP 0.995 0.82 0.54 0.17 0.99 0.98 0.985 0.78 0.945
Low power
CXCR6 0.025 0.015 0.005 0.01 0.025 0.03 0.025 0.035 0.025
PAK2 0.04 0.025 0.04 0.005 0.035 0.045 0.045 0.015 0.025
PTPLB 0.02 0.0 0.025 0.035 0.01 0.005 0.015 0.025 0.01
RAD18 0.025 0.005 0.05 0.04 0.005 0.005 0.02 0.015 0.01
Other representative genes
PDCD6IP 0.32 0.03 0.05 0.015 0.30 0.10 0.13 0.035 0.11
ZBTB38 0.09 0.325 0.10 0.21 0.08 0.295 0.07 0.325 0.19
Mean Across All 30 Genes (SD) 0.18 (0.25) 0.18 (0.23) 0.08 (0.11) 0.11 (0.18) 0.22 (0.30) 0.20 (0.25) 0.17 (0.27) 0.17 (0.23) 0.17 (0.25)
Statistical power is reported for all 9 tests across 10 different genes: the 4 genes with highest overall power, the 4 genes with lowest overall power, and 2 genes













Fig. 1 Empirical power of all 9 family-based rare-variant tests of
association for 2 genes of interest, PDCD6IP and ZBTB38. When
performing family-based rare-variant tests of association on gene
PDCD61P, wi-weighted tests (Q2, Q1, Q3, Q4) saw higher empirical
power than wi-weighted tests (Q2*, Q1*, Q4*, Q3*); for gene ZBTB38,
this trend was reversed. The combined test (black) maintained
consistent power between the 2 genes, and was less susceptible to
the change in genetic architecture
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attributed to the fact that wi less dramatically down-
weights common variants relative to rare variants than
does wi . This phenomenon is particularly evident in 2
genes: PDCD6IP, which contains a number of highly
causal rare variants, and ZBTB38, which contains several
causal common variants (Fig. 1). In each case, however,
the combined test strikes a middle ground: not quite as
strong as the better-chosen weights, but superior to the
poorer weights (Fig. 1).
Correlation between tests
Pairwise correlation between p values of different tests
was generally high with an average pairwise correlation
of 0.78 (SD = 0.16; min = 0.42; max = 0.98; detailed results
not shown).
Discussion
Few current methods allow for a flexible combination of
family-based rare-variant tests of association. In re-
sponse, we propose an adaptable framework for combin-
ing any number and type of gene-based rare-variant
tests on pedigree data that condition on genotype data.
Unlike current existing combination methods, our pro-
posed method does not limit the researcher to combin-
ing just 1 family-based burden test with 1 family-based
variance-component test, but instead allows for the
combination of an arsenal of varied and specialized tests.
Our proposed method also offers a distinct advantage
over simply running all possible individual tests and
choosing the most significant result; our combination
approach appropriately controls for multiple testing and
for the correlation between tests. When applied to the
The Author(s) BMC Proceedings 2016, 10(Suppl 7):23 Page 169 of 415GAW19 data, the combination method appeared to suf-
ficiently maintain type I error and demonstrated gener-
ally robust statistical power, even when applied to a wide
variety of genetic architectures, or when low-powered
tests were included.
However, our current approach does have several
limitations. In the above proof-of-concept application,
the combined test incorporates 8 highly correlated indi-
vidual tests of association; the additional noise from this
correlation diminishes the power of the combined test
to detect any meaningful genotype–phenotype associa-
tions. Further research is needed to explore what com-
bination of tests minimizes such correlation while also
maximizing statistical power. Further work is also neces-
sary to evaluate the benefits and drawbacks of different
choices of combined test statistics (eg, alternatives to
using the minimum p value).The permutation compo-
nent of our combination approach also poses computa-
tional challenges. The process of calculating p values
when asymptotic distributions have not been derived is
time intensive. The tests evaluated here were applied to
only 30 genes in a single simulated data set. We note
that if combining tests with known asymptotic distribu-
tions, it is straightforward to utilize asymptotically ob-
tained p values from individual tests when creating p jð Þ .
Further testing and evaluation on other data sets with
different characteristics is necessary. A single family-
based rare-variant test of association, if properly chosen
and adapted to match the genetic architecture, will al-
ways be more powerful than a combined approach. That
being said, researchers may not definitively know what
the underlying genetic architecture is, and there is al-
ways a tradeoff between power and robustness. Given
this, combined tests on family-based rare-variant data
show promise for ensuring the robustness of statistical
power to different genetic architectures with minimal
power loss. Finally, the permutation approach proposed
here relies on the assumption that the regression model
is true under the genetic null hypothesis, which will
rarely be true in practice. However, both Chen et al. [2]
and our results suggest that the type I error rate is
controlled in practice. Further research is necessary to
explore whether samples and conditions exists where
the type I error rate will increase.Conclusions
Our analysis acts as a proof-of-concept for combined
tests on family-based rare-variant data. In particular, our
analysis suggests that the type I error rate is controlled
by the proposed method, while power may be more ro-
bust to differing genetic architectures than individual,
gene-based rare-variant tests. Further work is needed to
explore the trade-off between combining many testsversus combining a smaller set of diverse tests in other
data sets/genes to ensure transferability of these findings.
Additionally, we need to explore alternatives to permuta-
tion strategies to compute statistical significance resulting
from the inherent computational limitations of this
approach.
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